Literature DB >> 17898005

Parkinson's disease, sleepiness and hypocretin/orexin.

Christian R Baumann, Thomas E Scammell, Claudio L Bassetti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17898005     DOI： 10.1093/brain/awm220

Source DB:  PubMed          Journal:  Brain        ISSN： 0006-8950            Impact factor:   13.501


× No keyword cloud information.
  10 in total

1.  Early Sociability and Social Memory Impairment in the A53T Mouse Model of Parkinson's Disease Are Ameliorated by Chemogenetic Modulation of Orexin Neuron Activity.

Authors:  Milos Stanojlovic; Jean Pierre Pallais Yllescas; Aarthi Vijayakumar; Catherine Kotz
Journal:  Mol Neurobiol       Date:  2019-06-27       Impact factor: 5.590

2.  Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson's disease.

Authors:  Milos Stanojlovic; Jean Pierre Pallais; Michael K Lee; Catherine M Kotz
Journal:  Mol Brain       Date:  2019-10-30       Impact factor: 4.041

3.  SLEEP AND CIRCADIAN RHYTHM DISORDERS IN PARKINSON'S DISEASE.

Authors:  Priti Gros; Aleksandar Videnovic
Journal:  Curr Sleep Med Rep       Date:  2017-07-06

4.  Sleep disturbances associated with Parkinson's disease.

Authors:  Keisuke Suzuki; Masayuki Miyamoto; Tomoyuki Miyamoto; Masaoki Iwanami; Koichi Hirata
Journal:  Parkinsons Dis       Date:  2011-08-17

Review 5.  Inflammation-sleep interface in brain disease: TNF, insulin, orexin.

Authors:  Ian A Clark; Bryce Vissel
Journal:  J Neuroinflammation       Date:  2014-03-21       Impact factor: 8.322

6.  Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson's Disease.

Authors:  Mei-Fang Liu; Yan Xue; Cui Liu; Yun-Hai Liu; Hui-Ling Diao; Ying Wang; Yi-Peng Pan; Lei Chen
Journal:  Front Neurosci       Date:  2018-11-15       Impact factor: 4.677

7.  Chemogenetic Modulation of Orexin Neurons Reverses Changes in Anxiety and Locomotor Activity in the A53T Mouse Model of Parkinson's Disease.

Authors:  Milos Stanojlovic; Jean Pierre Pallais; Catherine M Kotz
Journal:  Front Neurosci       Date:  2019-07-30       Impact factor: 4.677

8.  Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinson's Disease.

Authors:  Milos Stanojlovic; Jean Pierre Pallais; Catherine M Kotz
Journal:  Int J Mol Sci       Date:  2021-01-14       Impact factor: 5.923

Review 9.  Hypocretin (orexin) regulation of sleep-to-wake transitions.

Authors:  Luis de Lecea; Ramón Huerta
Journal:  Front Pharmacol       Date:  2014-02-12       Impact factor: 5.810

10.  Ventricular orexin-A (hypocretin-1) levels correlate with rapid-eye-movement sleep without atonia in Parkinson's disease.

Authors:  Agathe Bridoux; Stephane Moutereau; Ala Covali-Noroc; Laurent Margarit; Stephane Palfi; Jean-Paul Nguyen; Jean-Pascal Lefaucheur; Pierre Césaro; Marie-Pia d'Ortho; Xavier Drouot
Journal:  Nat Sci Sleep       Date:  2013-06-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.